Business
The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025
CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payable
About this update from The Oncology Institute, Inc.
[{"type":"image","alt":"Toi Management, LLC","displaySize":"","headline":null,"caption":"Toi Management, LLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":248,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/38271848c3d8a5e1e22cde43512eba2e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yhdVXLCOU06mfTSW3.iIsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/38271848c3d8a5e1e22cde43512eba2e","width":248,"height":86}},"lazy":false},{"type":"text","content":"CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024.","length":295,"tagName":"p"},{"type":"text","content":"Recent Operational Highlights","length":29,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"Selling, general, and administrative expenses decreased 12% in Q4 2024 as compared to the prior year period, as a result of our ongoing efforts to streamline operations, improve efficiency, and optimize our overhead resourcing.","length":227,"tagName":"p"}]},{"val":[{"type":"text","content":"Entered into a new agreement with our primary drug supplier, improving discounts across the board, including volume based discounts, which optimize our cost positioning as we work towards our revenue growth targets.","length":215,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched six new contracts across the third and fourth quarter totaling over 250,000 lives. Value-based patient services increased sequentially by over 15% from Q3 2024, with further revenue upside anticipated as these contracts mature.","length":236,"tagName":"p"}]},{"val":[{"type":"text","content":"Achieved a record quarter of revenue for the pharmaceutical dispensary revenue, which has continued to see increased attachment to clinic visits overall, including from our retail pharmacy in California, which has now lapped a full year of operation af...